Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Stevanato Group ( (STVN) ) has provided an announcement.
Stevanato Group S.p.A. is an Italy-based provider of drug containment and delivery solutions for the biopharmaceutical and diagnostic sectors, with a focus on high-value injectable platforms and proprietary pen injectors. Its global footprint, including facilities in the U.S., Germany and Italy, supports end-to-end offerings from primary packaging to advanced drug delivery devices.
On August 4, 2026, Stevanato reported half-year and second-quarter 2026 results showing 8% revenue growth to €302 million and an adjusted EBITDA margin of 26%, driven by a richer mix of high-value solutions. The group exited its Balda C. Brewer unit to sharpen its focus on complex integrated systems, advanced projects at Fishers and Latina to expand vial, syringe and cartridge capacity, and secured European approval for an Alina-based liraglutide therapy while launching the Deora fixed-dose pen, moves that bolster its position in fast-growing biologics and GLP-1 markets.
The most recent analyst rating on (STVN) stock is a Hold
with a $20.00 price target.
To see the full list of analyst forecasts on Stevanato Group stock,
see the STVN Stock Forecast page.
Spark’s Take on STVN Stock
According to Spark, TipRanks’ AI Analyst, STVN is a Neutral.
The score is driven primarily by strong growth and supportive technical momentum, reinforced by constructive guidance and operational highlights from the earnings call. The main constraints are weaker cash-flow conversion/FCF volatility and a less attractive valuation (high P/E with a very low dividend yield).
To see Spark’s full report on STVN stock,
click here.
More about Stevanato Group
Stevanato Group S.p.A. is an Italy-based provider of drug containment and delivery solutions for the biopharmaceutical and diagnostic industries. The company focuses on high-value injectable platforms, including glass vials, syringes, cartridges and proprietary pen injectors, and operates engineering services that support integrated drug delivery systems for global pharma and biotech customers.
Its portfolio targets fast-growing markets such as biologics and GLP-1 therapies, emphasizing device innovation, manufacturing expertise and supply chain reliability. Facilities in the U.S., Germany and Italy underpin its strategy to offer end-to-end solutions, from primary packaging to advanced drug delivery devices, aimed at improving patient usability and adherence.
Stevanato Group reported its half-year and second-quarter 2026 results on August 4, 2026, noting 8% year-on-year revenue growth to €302 million and an adjusted EBITDA margin of 26%. Growth was driven by a 9% increase in the Biopharmaceutical and Diagnostic Solutions segment and a richer mix of high-value solutions, which offset a modest 2% revenue decline in the Engineering segment.
Management highlighted strong momentum in biologics and GLP-1 therapies, with high-value solutions up 16% and now representing 45% of company revenue, and GLP-related products accounting for roughly 22% to 23%. The firm completed the divestiture of its California-based Balda C. Brewer unit to sharpen its focus on more complex, differentiated and integrated drug delivery systems, signaling continued portfolio optimization.
Operationally, Stevanato advanced key growth projects, including performance qualification of its first EZ-fill vial line and preparation for device commercial production later in 2026 at its Fishers, U.S. site. In Latina, Italy, syringe ramp-up continued and installation of a next-generation RTU 400 cartridge line is expected in the coming months, with commercial output planned for 2027, reinforcing capacity for premium containment solutions.
The company also underscored strategic product milestones, citing European regulatory approval of a liraglutide therapy using its Alina variable-dose pen platform for diabetes and weight management and the recent launch of Deora, a multi-use fixed-dose pen system. These developments, alongside ongoing improvements in the Engineering segment, are intended to strengthen Stevanato’s positioning in high-growth injectable markets and support long-term value for pharmaceutical partners and investors.
Average Trading Volume: 362,968
Technical Sentiment Signal: Buy
Current Market Cap: $5.42B
Learn more about STVN stock on TipRanks’ Stock Analysis page.